Related Experiment Videos
Nonarteritic anterior ischemic optic neuropathy
1Department of Ophthalmology, University of Maryland, Baltimore, Maryland 21201, USA. m.km@earthlink.net
Current Opinion in Ophthalmology
|November 3, 2005
Summary
Nonarteritic anterior ischemic optic neuropathy (NAION) is poorly understood, with variable presentations and no proven treatments. Ongoing research aims to clarify risk factors and develop effective prevention and management strategies.
Area of Science:
- Ophthalmology
- Neurology
- Vascular Medicine
Background:
- Nonarteritic anterior ischemic optic neuropathy (NAION) presents variably, complicating diagnosis compared to classic symptoms.
- Differentiating NAION from optic neuritis and arteritic ischemic optic neuropathy is challenging due to its diverse clinical manifestations.
- The condition can affect the fellow eye sequentially, highlighting its unpredictable nature.
Purpose of the Study:
- To review the current understanding of nonarteritic anterior ischemic optic neuropathy (NAION).
- To explore proposed risk factors and underlying mechanisms of NAION.
- To summarize investigated treatment options and the need for further research.
Main Methods:
- Review of existing literature on NAION.
- Analysis of proposed risk factors and etiological hypotheses.
- Evaluation of investigated therapeutic interventions.
Main Results:
- Visual recovery in NAION is inconsistent.
- Proposed risk factors include crowded disc, atherosclerosis, diabetes, hypertension, and hypercoagulable states.
- Optic nerve damage stems from perfusion insufficiency in posterior ciliary arteries, but mechanisms remain unclear; no definitive treatment exists.
Conclusions:
- Current understanding of NAION's risk factors and pathophysiology is incomplete.
- No proven effective treatments are currently available for NAION.
- Further research in humans and animals is crucial for advancing prevention and treatment strategies.